Future perspectives for advancing regulatory science of nanotechnology-enabled health products

[1]  N. Roth,et al.  Development of the SciRAP Approach for Evaluating the Reliability and Relevance of in vitro Toxicity Data , 2021, Frontiers in Toxicology.

[2]  Christopher A. W. David,et al.  Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[3]  B. Halamoda-Kenzaoui,et al.  Toxic effects of nanomaterials for health applications: How automation can support a systematic review of the literature? , 2021, Journal of applied toxicology : JAT.

[4]  Rogério Sá Gaspar,et al.  Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision , 2020, Frontiers in Medicine.

[5]  A. Owen,et al.  Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products , 2020 .

[6]  H. Leufkens,et al.  The EU regulatory landscape of non‐biological complex drugs (NBCDs) follow‐on products: Observations and recommendations , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  U. Holzwarth,et al.  Mapping of the available standards against the regulatory needs for nanomedicines , 2018, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[8]  Bremer Susanne,et al.  Anticipation of regulatory needs for nanotechnology-enabled health products , 2019 .

[9]  Edmund J. Crampin,et al.  Minimum information reporting in bio–nano experimental literature , 2018, Nature Nanotechnology.

[10]  Marc Aerts,et al.  Machine learning techniques for the automation of literature reviews and systematic reviews in EFSA , 2018, EFSA Supporting Publications.

[11]  L. Lukasse.  The use of USDA sensors as calibrated temperature recorders : In view of EU guidelines on GDP for medicinal products for human use , 2016 .

[12]  Beat Flühmann,et al.  The similarity question for biologicals and non-biological complex drugs. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Gerrit Borchard,et al.  Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars. , 2015, Nanomedicine.

[14]  R. Duncan,et al.  Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. , 2013, Nanomedicine.

[15]  COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS , 2008 .